The stream · Daily digest
The stream: Sunday, October 11, 2026
4 briefs, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 4
-
NOPARK trial reports nicotinamide riboside does not improve clinical outcomes in Parkinson disease
The authors reported that among 393 participants, the total MDS-UPDRS score increased by 2.45 points with nicotinamide riboside and decreased by 0.27 points with placebo, yielding an adjusted mean difference of 2.72 points favoring placebo. Non-motor symptom burden worsened more with nicotinamide riboside, with an adjusted mean difference of 4.22 points.
Source: PubMed record of a Phase III journal article, October 8, 2026
-
RINGSIDE Phase II Study of Varegacestat for Desmoid Tumors
The authors reported that 42 participants were randomized to three dose regimens of varegacestat, with median tumor volume reductions at week 16 of -51.91%, -15.25% and -9.50% for the 1.2-mg once-daily, 2-mg intermittent and 4-mg intermittent doses, respectively. In the open-label extension, 29 participants received 1.2-mg once-daily and achieved a median best tumor volume change of -85.88% and a confirmed objective response rate of 57.1%.
Source: PubMed record of a Phase III journal article, October 8, 2026
-
Lilly releases new exploratory data from TOGETHER-PsO Phase 3b trial
The company announced exploratory biomarker data from the TOGETHER-PsO Phase 3b study showing broader immune and metabolic changes when Taltz (ixekizumab) and Zepbound (tirzepatide) were used together versus Taltz alone. The analysis reported 482 versus 140 differentially expressed proteins and 467 versus 16 genes at Week 36, with greater reductions in inflammatory immune activity.
Source: Company press release (PR Newswire), October 9, 2026
-
BioMarin presents new VOXZOGO data at ASBMR 2026
BioMarin will present new data from 13 studies, including a randomized, double-blind, placebo-controlled trial on VOXZOGO's effect on foramen magnum and craniocervical junction growth in children with achondroplasia. The company will also share data on the investigational long-acting medicine BMN 333 and on VOXZOGO's potential use in hypochondroplasia, for which it has submitted a supplemental New Drug Application.
Source: Company press release (PR Newswire), October 9, 2026